FY2025 Earnings Forecast for TEVA Issued By Zacks Research

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research cut their FY2025 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research note issued on Wednesday, March 5th. Zacks Research analyst R. Department now expects that the company will post earnings of $2.42 per share for the year, down from their previous forecast of $2.52. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.48 EPS and FY2026 earnings at $2.55 EPS.

Other equities analysts have also issued reports about the company. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America lowered their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday. Finally, UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $15.34 on Friday. Teva Pharmaceutical Industries has a 12 month low of $12.51 and a 12 month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a market cap of $17.40 billion, a P/E ratio of -10.58, a P/E/G ratio of 1.44 and a beta of 0.71. The business’s 50 day moving average is $18.85 and its two-hundred day moving average is $18.38.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $44,000. Smithfield Trust Co boosted its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Finally, Venturi Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.